Well PMCB is doing this to be listed on the NASD and that is fine with me and any hedge fund then they can buy shares of PMCB if they are on the NASD and above $5.00. Lets not forget about our Partner doing their IPO and we own 15% of them.
Many buyers will want to own PMCB for the Inside price on the IPO
Austrianova Secures $100 Million USD Investment Commitment from GEM as Company Seeks to Go PublicEncapsulation of cells and bacteria using Austrianova's Cell-in-a-Box and Bac-in-a-Box technologiesCell-in-a-Box and Bac-in-a-Box technologies
Singapore based Company envisages going public via SPAC merger or traditional IPO We believe that this is the largest share subscription facility to date for an Asian-based biotech company”— Brian Salmons, CEOSINGAPORE, April 22, 2021 /EINPresswire.com/ -- Austrianova (the SG Austria group, Austrianova Singapore and Austrianova Thailand) is pleased to announce that it has signed an Agreement with GEM Global Yield LLC SCS ("GEM"), the Luxembourg based private alternative investment group, to provide Austrianova with a share subscription facility of up to $100 million USD for a 36-month term following a public listing. The share subscription facility, will allow Austrianova, subject to the further terms, to draw down funds by issuing shares of common stock to GEM. Austrianova will control the timing and the maximum size of such drawdowns and has no minimum drawdown obligation.Austrianova has issued warrants to GEM, exercisable upon public listing, to purchase up to 4.2% of the common stock of the company.This announcement occurs as the Company embarks on its next stage of growth in production capacity in order to satisfy the strong demand witnessed across the wide variety of applications that its unique protective cell encapsulation technology addresses. Austrianova was advised on strategic and financial matters by Square Associates (Singapore) and on legal matters by Luther LLP."This Agreement with GEM helps secure funding for continued growth and development of Austrianova as we continue to expand the number of partners using our Cell-in-a-Box® and Bac-in-a-Box® technologies" stated Walter H Gunzburg, Chairman of Austrianova.
“With certainty of capital upon listing on a national public stock exchange, Austrianova is now well-positioned as the company enters its next stage of development. We believe that this is the largest share subscription facility for an Asian-based biotech company.” added Brian Salmons, CEO of Austrianova.About AustrianovaAustrianova (the SG Austria Group), is a biotech company with a global footprint and operations in Singapore and Thailand. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications as well as rebalancing the microbiome due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid. Austrianova now also offers GMP4Cells that includes competitively priced Master Cell Bank and Working Cell Bank production as well as “Fill and Finish” services for cell therapy products (such as stem cell therapies, biologics produced from cells e.g. vaccines, antibodies, enzymes, recombinant proteins, exosomes etc).Austrianova Secures $100 Million USD Investment Commitment from GEM as Company Seeks to Go PublicNEWS PROVIDED BYAustrianovaApril 22, 2021, 07:09 GMTSHARE THIS ARTICLELogos of Austrianova and its Cell-in-a-Box and Bac-in-a-Box encapsulation technologiesEncapsulation of cells and bacteria using Austrianova's Cell-in-a-Box and Bac-in-a-Box technologiesCell-in-a-Box and Bac-in-a-Box technologies explainedVials of Austrianova's Cell-in-a-Box and of Bac-in-a-BoxCell-in-a-Box and Bac-in-a-Box CapsulesSingapore based Company envisages going public via SPAC merger or traditional IPOWe believe that this is the largest share subscription facility to date for an Asian-based biotech company”— Brian Salmons, CEOSINGAPORE, April 22, 2021 /EINPresswire.com/ -- Austrianova (the SG Austria group, Austrianova Singapore and Austrianova Thailand) is pleased to announce that it has signed an Agreement with GEM Global Yield LLC SCS ("GEM"), the Luxembourg based private alternative investment group, to provide Austrianova with a share subscription facility of up to $100 million USD for a 36-month term following a public listing. The share subscription facility, will allow Austrianova, subject to the further terms, to draw down funds by issuing shares of common stock to GEM. Austrianova will control the timing and the maximum size of such drawdowns and has no minimum drawdown obligation.Austrianova has issued warrants to GEM, exercisable upon public listing, to purchase up to 4.2% of the common stock of the company.This announcement occurs as the Company embarks on its next stage of growth in production capacity in order to satisfy the strong demand witnessed across the wide variety of applications that its unique protective cell encapsulation technology addresses.
Austrianova was advised on strategic and financial matters by Square Associates (Singapore) and on legal matters by Luther LLP."This Agreement with GEM helps secure funding for continued growth and development of Austrianova as we continue to expand the number of partners using our Cell-in-a-Box® and Bac-in-a-Box® technologies" stated Walter H Gunzburg, Chairman of Austrianova. “With certainty of capital upon listing on a national public stock exchange, Austrianova is now well-positioned as the company enters its next stage of development. We believe that this is the largest share subscription facility for an Asian-based biotech company.” added Brian Salmons, CEO of Austrianova.About AustrianovaAustrianova (the SG Austria Group), is a biotech company with a global footprint and operations in Singapore and Thailand. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications as well as rebalancing the microbiome due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid. Austrianova now also offers GMP4Cells that includes competitively priced Master Cell Bank and Working Cell Bank production as well as “Fill and Finish” services for cell therapy products (such as stem cell therapies, biologics produced from cells e.g. vaccines, antibodies, enzymes, recombinant proteins, exosomes etc).
